# Bluebird Bio

Type: Company (BLUE)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/bluebird-bio
Canonical HTML page: https://getbiobrief.com/entity/bluebird-bio

## Recent coverage (1 stories)

### Casgevy Wins FDA Nod for Kids 2+, Widening $2.2M Gene Therapy Duel
2026-07-09 07:50:38 · Sentiment: Positive · Impact: 8/10 · Sources: 20

The FDA's expansion of Casgevy to children aged 2–11 solidifies Vertex and CRISPR Therapeutics' lead over bluebird bio’s Lyfgenia, opens a lucrative new patient segment, and validates the safety of CRISPR gene editing in very young patients.
Full story: https://getbiobrief.com/story/crispr-casgevy-pediatric-fda-approval-bio

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.